Eliquis (Apixaban) Patent Expiration, LOE Window & CMS Spending
Eliquis (Apixaban) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2027-05-21 (last listed 2031-08-24), 2 AB generics, $22.07B 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N202155 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2027-05-21 |
| Last Listed Patent or Exclusivity Date | 2031-08-24 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $22.07B |
| 2024 Medicare Part D Spend | $20.77B |
| 2024 Medicaid Spend | $1.29B |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 19.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.